Ligand id: 5004

Name: infliximab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: infliximab

Compound class Antibody
Approved drug? Yes (FDA (1998), EMA (1999))
International Nonproprietary Names
INN number INN
7602 infliximab
cA2 | Inflectra® | Remicade® | Remsima® | SB2 | TA-650
Database Links
Specialist databases
IMGT/mAb-DB 156
Other databases
PubChem SID 178101701
Search PubMed clinical trials infliximab
Search PubMed titles infliximab
Search PubMed titles/abstracts infliximab
Wikipedia Infliximab
Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 [4].

Biosimilar drugs: In 2016 biosimilar agent CT-P13 (developed by Celltrion, also known as infliximab-dyyb; Remsima®, Inflectra®) was approved in several countries for use in all indications for which reference infliximab is approved [1-2,7]. Although the approval covers the same indicated conditions as the reference drug, it should be noted that CT-P13 is approved as a biosimilar and not as an interchangeable product. Flixabi® (a.k.a. Renflexis®, SB2, infliximab-abda), another infliximab biosimilar (manufactured and commercialized by Biogen in the EU) received EMA marketing authorisation in 2016, followed by FDA approval in April 2017. PF-06438179 is another potential biosimilar to infliximab being developed by Pfizer Inc. [3].